Ann Marie Navar-Boggan1, Eric D Peterson2, Ralph B D'Agostino3, Michael J Pencina2, Allan D Sniderman4. 1. Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina. Electronic address: ann.navar@dm.duke.edu. 2. Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina. 3. Department of Mathematics and Statistics, Boston University, Boston, Massachusetts; Harvard Clinical Research Institute, Boston, Massachusetts. 4. Mike Rosenbloom Laboratory for Cardiovascular Research, McGill University Health Centre, Royal Victoria Hospital, Montreal, Canada.
Abstract
BACKGROUND: New cholesterol guidelines emphasize 10-year risk of cardiovascular disease (CVD) to identify adults eligible for statin therapy as primary prevention. Whether these CVD risk thresholds should be individualized by age and sex has not been explored. OBJECTIVES: This study evaluated the potential impact of incorporating age- and sex-specific CVD risk thresholds into current cholesterol guidelines. METHODS: Using data from the Framingham Offspring Study, this study assessed current treatment recommendations among age- and sex-specific groups in 3,685 participants free of CVD. Then, it evaluated how varying age- and sex-specific 10-year CVD risk thresholds for statin treatment affect the sensitivity and specificity for incident 10-year CVD events. RESULTS: Basing statin therapy recommendations on a 10-year fixed risk threshold of 7.5% results in lower statin consideration among women than men (63% vs. 33%; p<0.0001), yet most of the study participants who were 66 to 75 years of age were recommended for statin treatment (90.3%). The fixed 7.5% threshold had relatively low sensitivity for capturing 10-year events in younger women and men (40 to 55 years of age). Sensitivity of the recommendations was substantially improved when the treatment threshold was reduced to 5% in participants who were 40 to 55 years of age. Among older adults (66 to 75 years of age), specificity was poor, but when the treatment threshold was raised to 10% in women and 15% in men, specificity significantly improved, with minimal loss in sensitivity. CONCLUSIONS: Cholesterol treatment recommendations could be improved by using individualized age- and sex-specific CVD risk thresholds.
BACKGROUND: New cholesterol guidelines emphasize 10-year risk of cardiovascular disease (CVD) to identify adults eligible for statin therapy as primary prevention. Whether these CVD risk thresholds should be individualized by age and sex has not been explored. OBJECTIVES: This study evaluated the potential impact of incorporating age- and sex-specific CVD risk thresholds into current cholesterol guidelines. METHODS: Using data from the Framingham Offspring Study, this study assessed current treatment recommendations among age- and sex-specific groups in 3,685 participants free of CVD. Then, it evaluated how varying age- and sex-specific 10-year CVD risk thresholds for statin treatment affect the sensitivity and specificity for incident 10-year CVD events. RESULTS: Basing statin therapy recommendations on a 10-year fixed risk threshold of 7.5% results in lower statin consideration among women than men (63% vs. 33%; p<0.0001), yet most of the study participants who were 66 to 75 years of age were recommended for statin treatment (90.3%). The fixed 7.5% threshold had relatively low sensitivity for capturing 10-year events in younger women and men (40 to 55 years of age). Sensitivity of the recommendations was substantially improved when the treatment threshold was reduced to 5% in participants who were 40 to 55 years of age. Among older adults (66 to 75 years of age), specificity was poor, but when the treatment threshold was raised to 10% in women and 15% in men, specificity significantly improved, with minimal loss in sensitivity. CONCLUSIONS:Cholesterol treatment recommendations could be improved by using individualized age- and sex-specific CVD risk thresholds.
Authors: Paul Muntner; Lisandro D Colantonio; Mary Cushman; David C Goff; George Howard; Virginia J Howard; Brett Kissela; Emily B Levitan; Donald M Lloyd-Jones; Monika M Safford Journal: JAMA Date: 2014-04-09 Impact factor: 56.272
Authors: Neil J Stone; Jennifer G Robinson; Alice H Lichtenstein; C Noel Bairey Merz; Conrad B Blum; Robert H Eckel; Anne C Goldberg; David Gordon; Daniel Levy; Donald M Lloyd-Jones; Patrick McBride; J Sanford Schwartz; Susan T Shero; Sidney C Smith; Karol Watson; Peter W F Wilson; Karen M Eddleman; Nicole M Jarrett; Ken LaBresh; Lev Nevo; Janusz Wnek; Jeffrey L Anderson; Jonathan L Halperin; Nancy M Albert; Biykem Bozkurt; Ralph G Brindis; Lesley H Curtis; David DeMets; Judith S Hochman; Richard J Kovacs; E Magnus Ohman; Susan J Pressler; Frank W Sellke; Win-Kuang Shen; Sidney C Smith; Gordon F Tomaselli Journal: Circulation Date: 2013-11-12 Impact factor: 29.690
Authors: David C Goff; Donald M Lloyd-Jones; Glen Bennett; Sean Coady; Ralph B D'Agostino; Raymond Gibbons; Philip Greenland; Daniel T Lackland; Daniel Levy; Christopher J O'Donnell; Jennifer G Robinson; J Sanford Schwartz; Susan T Shero; Sidney C Smith; Paul Sorlie; Neil J Stone; Peter W F Wilson; Harmon S Jordan; Lev Nevo; Janusz Wnek; Jeffrey L Anderson; Jonathan L Halperin; Nancy M Albert; Biykem Bozkurt; Ralph G Brindis; Lesley H Curtis; David DeMets; Judith S Hochman; Richard J Kovacs; E Magnus Ohman; Susan J Pressler; Frank W Sellke; Win-Kuang Shen; Sidney C Smith; Gordon F Tomaselli Journal: Circulation Date: 2013-11-12 Impact factor: 29.690
Authors: Ewout W Steyerberg; Andrew J Vickers; Nancy R Cook; Thomas Gerds; Mithat Gonen; Nancy Obuchowski; Michael J Pencina; Michael W Kattan Journal: Epidemiology Date: 2010-01 Impact factor: 4.822
Authors: Michael J Pencina; Ann Marie Navar-Boggan; Ralph B D'Agostino; Ken Williams; Benjamin Neely; Allan D Sniderman; Eric D Peterson Journal: N Engl J Med Date: 2014-03-19 Impact factor: 91.245
Authors: Avinainder Singh; Bradley L Collins; Ankur Gupta; Amber Fatima; Arman Qamar; David Biery; Julio Baez; Mary Cawley; Josh Klein; Jon Hainer; Jorge Plutzky; Christopher P Cannon; Khurram Nasir; Marcelo F Di Carli; Deepak L Bhatt; Ron Blankstein Journal: J Am Coll Cardiol Date: 2017-11-12 Impact factor: 24.094
Authors: Ciaran N Kohli-Lynch; James Lewsey; Kathleen A Boyd; Dustin D French; Neil Jordan; Andrew E Moran; Naveed Sattar; David Preiss; Andrew H Briggs Journal: Circulation Date: 2022-03-07 Impact factor: 39.918